Anti-Human EG-VEGF
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Goat Immunogen Purified Recombinant Human EG-VEGF (>98%) Endotoxin Level <0.4 EU/µg as determined by the LAL method Formulation This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present. State of Matter Lyophilized Storage and Handling The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months. Country of Origin USA Shipping Next Day Ambient RRIDAB_2829993 Applications and Recommended Usage? Quality Tested by Leinco Western Blotting: To detect Human EG-VEGF this polyclonal antibody can be used at a concentration of 0.1-0.2 µg/ml. This polyclonal antibody should be used in conjunction with compatible second-step reagents such as PN:G505 and a chromogenic substrate such as PN:T343. The detection limit for Human EG-VEGF is 1 ng/lane or 5 ng/lane under reducing or non-reducing conditions, respectively. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:V108. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Goat Anti-Human Endocrine Gland-Derived Endothelial Growth Factor (EG-VEGF) recognizes Human EG-VEGF. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research. Background Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) or Prokineticin-1 (PK-1) is a novel secreted protein expressed in various tissues including steroidogenic glands. Although structurally non-related to VEGF, EG-VEGF/PK-1 was shown to promote angiogenesis acting via two G-protein coupled receptors (PK-R1 and PK-R2). 1 EG-VEGF is mitogen specific for the endothelium of steroidogenic glands. It induces proliferation, migration and fenestration in capillary endothelial cells derived from endocrine glands. EG-VEGF mRNA expression is localized to the steroid hormone-producing cells, i.e. Leydig cells of the testis and the specialized stroma in the ovary. 2 EG-VEGF increased the phosphorylation of Akt in a phosphatidylinositol 3-kinase-dependent manner and is a survival factor for ACE cells. EG-VEGF, possibly through binding to a G-protein coupled receptor, results in the activation of MAPK p44/42 and phosphatidylinositol 3-kinase signaling pathways, leading to proliferation, migration, and survival of responsive endothelial cells. 3 Antigen Distribution Human EG-VEGF is a secreted angiogenetic mitogen growth factor expressed in the steroidogenic glands, ovary, testis, adrenal and placenta. PubMed NCBI Gene Bank ID UniProt.org References & Citations1. Meidan, R. et al. (2005) Endocrinology. 146(9):3950-8. 2. Ferrara, N. et al. (2002) Cold Spring Harb Symp Quant Biol.67:217-21. 3. Ferrara, N. et al. (2002) J Biol Chem. 277(10):8724-9. Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Prod No. | Description |
---|---|
E146 | |
E190 | |
E320 | |
V108 | |
E147 |
